文献速递妇科

PARP抑制剂奥拉帕利与pan-ErbB抑制剂来那替尼在HER2过表达上皮性卵巢癌体外和体内高度协同

The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo.
PubMed 文献 · Gynecol Oncol · 2023-01-25

该临床前研究评估了PARP抑制剂奥拉帕利与pan-ErbB抑制剂来那替尼单药及联合在HER2表达不同的卵巢癌细胞系和异种移植瘤中的疗效。HER2阳性卵巢癌细胞系对奥拉帕利和来那替尼的敏感性高于HER2阴性者,两药联合在体外和体内均较单药更有效并在所有HER2阳性原代模型中显示协同作用。作者认为该联合对HER2阳性、同源重组功能正常且化疗耐药的卵巢癌可能是一种新的治疗选择。

要点

  • HER2阳性卵巢癌细胞系对奥拉帕利和来那替尼的敏感性高于HER2阴性者。
  • 奥拉帕利与来那替尼联合在体外和体内均较单药更有效,并在所有HER2阳性原代模型中显示协同作用。
  • 作者认为该联合可能为HER2阳性、同源重组功能正常且化疗耐药的卵巢癌患者提供新的治疗选择。

核心结论

  • 奥拉帕利与来那替尼联合具有协同作用,在HER2阳性卵巢癌中表现出显著的临床前活性。
  • 该联合可能为HER2阳性、同源重组功能正常且化疗耐药的卵巢癌患者提供一种新的治疗选择。

研究设计与样本

  • 体外采用基于流式细胞术的检测方法,在HER2表达不同的卵巢癌原代细胞系中评估奥拉帕利、来那替尼及两药联合的细胞活力。
  • 体内在HER2阳性卵巢癌异种移植模型中比较奥拉帕利/来那替尼联合与单药的抗肿瘤活性。
  • 通过免疫印迹实验探讨药物活性与协同作用的机制。

主要发现

  • HER2阳性卵巢癌细胞系对奥拉帕利和来那替尼的敏感性高于HER2阴性肿瘤:奥拉帕利IC50为2.06 ± 0.33 μM vs. 39.28 ± 30.51 μM,p = 0.0035;来那替尼IC50为19.42 ± 2.63 nM vs. 235.0 ± 165.0 nM,p = 0.0035。
  • 奥拉帕利与来那替尼联合在体外和体内均较单药奥拉帕利或单药来那替尼更有效,并在所有HER2阳性原代卵巢癌模型中显示协同作用。
  • Western blot显示来那替尼降低pHER2/neu并增加聚(ADP-核糖)(PAR)酶活性;奥拉帕利增加pHER2/Neu表达并阻断PAR活化;两药联合同时降低pHER2/Neu和PAR活化。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Ovarian cancer (OC) is associated with the highest gynecologic cancer mortality. The development of novel, effective combinations of targeted therapeutics remains an unmet medical need. We evaluated the preclinical efficacy of the Poly (ADP-ribose) polymerase (PARP) inhibitor (olaparib) and the pan-ErbB inhibitor (neratinib) as single agents and in combination in ovarian cancer cell lines and xenografts with variable HER2 expression. METHODS: In vitro cell viability with olaparib, neratinib, and their combination was assessed using flow-cytometry based assays against a panel of OC primary cell lines with variable HER2 expression. Immunoblotting experiments were performed to elucidate the mechanism of activity and synergism. The in vivo antitumor activity of the olaparib/neratinib combination versus single agents was tested in HER2 positive xenograft OC models. RESULTS: HER2 + OC cell lines demonstrated higher sensitivity to olaparib and neratinib when compared to HER2 negative tumors (i.e., IC50: 2.06 ± 0.33 μM vs. 39.28 ± 30.51 μM, p = 0.0035 for olaparib and 19.42 ± 2.63 nM vs. 235.0 ± 165.0 nM, p = 0.0035 for neratinib). The combination of olaparib with neratinib was more potent when compared to single-agent olaparib or neratinib both in vitro and in vivo, and demonstrated synergy in all primary HER2 + OC models. Western blot experiments showed neratinib decreased pHER2/neu while increased Poly(ADP-ribose) (PAR) enzymatic activity; olaparib increased pHER2/Neu expression and blocked PAR activatio. Olaparib/neratinib in combination decreased both pHER2/Neu as well as PAR activation. CONCLUSION: The combination of olaparib and neratinib is synergistic and endowed with remarkable preclinical activity against HER2+ ovarian cancers. This combination may represent a novel therapeutic option for ovarian cancer patients with HER2+, homologous recombination-proficient tumors resistant to chemotherapy.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Han C, McNamara B, Bellone S, et al. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo. Gynecol Oncol. 2023. PMID: 36706643. doi:10.1016/j.ygyno.2023.01.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。